Cardiovascular disease: risk assessment and reduction, including lipid modification (NG238)Product type:GuidanceProgramme:NICE guidelinePublished: 14 December 2023
Automated ankle brachial pressure index measurement devices to detect peripheral arterial disease in people with leg ulcers (HTG677)Product type:GuidanceProgramme:HealthTech guidancePublished: 24 May 2023
Peripheral arterial disease: diagnosis and management (CG147)Product type:GuidanceProgramme:Clinical guidelineLast updated: 11 December 2020Published: 8 August 2012
Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease (TA607)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 17 October 2019
Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease (TA223)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 May 2011
Cardiovascular disease prevention (PH25)Product type:GuidanceProgramme:Public health guidelinePublished: 22 June 2010
Spinal cord stimulation for chronic pain of neuropathic or ischaemic origin (TA159)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 October 2008
PROPATEN heparin-bonded vascular graft for peripheral arterial disease (MIB42)Product type:AdviceProgramme:Medtech innovation briefingPublished: 13 October 2015
Spiral Flow peripheral vascular graft for treating peripheral arterial disease (MIB34)Product type:AdviceProgramme:Medtech innovation briefingPublished: 21 July 2015
Symptoms of peripheral arterial disease: ramipril (ESUOM45)Product type:AdviceProgramme:Evidence summaryPublished: 30 June 2015
Cardiovascular risk assessment and lipid modification (QS100)Product type:Quality standardLast updated: 23 July 2025Published: 4 September 2015
Semaglutide for treating type 2 diabetes and associated peripheral arterial disease [TSID11791]Status:Topic prioritisationProgramme:Technology appraisal guidanceExpected publication date: TBC
Pelacarsen for reducing the risk of cardiovascular events in people with established cardiovascular disease and high lipoprotein (a) [ID6559]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Tirzepatide for reducing the risk of major adverse cardiovascular events in people with type 2 diabetes and cardiovascular disease [TSID12347]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC